A cyclic adenosine monophosphate response element-binding protein inhibitor enhances the antibacterial activity of polymyxin B by inhibiting the ATP hydrolyzation activity of CrrB

Bibliographic Details
Title: A cyclic adenosine monophosphate response element-binding protein inhibitor enhances the antibacterial activity of polymyxin B by inhibiting the ATP hydrolyzation activity of CrrB
Authors: Wei Huang, Jinyong Zhang, Yuzhang He, Chunxia Hu, Shumin Cheng, Huan Zeng, Manling Zheng, Huijuan Yu, Xue Liu, Quanming Zou, Ruiqin Cui
Source: Frontiers in Pharmacology, Vol 13 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: antibiotic adjuvant, Klebsiella pneumoniae, polymyxin B resistant, lipid A, lipopolysaccharide, two-component system, Therapeutics. Pharmacology, RM1-950
More Details: The emergence of polymyxin B (PB) resistant Gram-negative bacteria poses an important clinical and public health threat. Antibiotic adjuvants development is a complementary strategy that fills the gap in new antibiotics. Here, we described the discovery of the enhancement capacity of compound 666-15, previously identified as an inhibitor of cyclic adenosine monophosphate response element-binding protein (CREB), on the activity of PB against Klebsiella pneumoniae in vitro and in vivo. Mechanistic studies showed that this compound reduced the transcription and translation levels of genes related to lipid A modification in the presence of PB. We also identified that 666-15 reduces the ATP hydrolyzation activity of CrrB, and P151L mutation mediates the resistance of bacteria to the enhancement of 666-15. Our results demonstrated the potential of 666-15 in clinical application and support the further development of a PB synergist based on this compound.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1663-9812
Relation: https://www.frontiersin.org/articles/10.3389/fphar.2022.949869/full; https://doaj.org/toc/1663-9812
DOI: 10.3389/fphar.2022.949869
Access URL: https://doaj.org/article/51107a7fb5114da4835c21ab68b7d43b
Accession Number: edsdoj.51107a7fb5114da4835c21ab68b7d43b
Database: Directory of Open Access Journals
More Details
ISSN:16639812
DOI:10.3389/fphar.2022.949869
Published in:Frontiers in Pharmacology
Language:English